High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients
- Conditions
- COVID-19 Pneumonia
- Registration Number
- NCT07213518
- Lead Sponsor
- Mansoura University
- Brief Summary
compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure
- Detailed Description
A prospective randomized controlled trial was conducted on 108 patients with COVID 19 pneumonia with acute hypoxemic respiratory failure at Mansoura University Hospitals to compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure, focusing on the need for invasive mechanical ventilation (IMV) and 28-day mortality. Patients were randomized into two equal groups: HVNI group and CPAP group. Baseline characteristics, respiratory parameters, and clinical outcomes were recorded.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 108
- Patients aged above 18 years with COVID 19 pneumonia with acute type 1 respiratory failure were included.
- patients with hypercapnic respiratory failure.
- patients with a disturbed level of consciousness and/or a high risk of aspiration
- individuals with hypotension
- patients requiring invasive mechanical ventilation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Correction of hypoxia in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure 6 months assessment of efficacy of High Velocity Nasal Insufflation versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mohamed AbdElmoniem
🇪🇬Al Mansurah, Egypt
Mohamed AbdElmoniem🇪🇬Al Mansurah, Egypt